Is this you?
Request access for East Texas Cardiology PA with your @estar.bio work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Intera lens
ICP 5Lift (cardio sample) 1.00Recruit soph 0
Quality Scorecard (1–100)
Overall68Recruit62Ops74Sponsor68Ther69
Performance (observed)
Historical trials
192
Completed
114
Terminated/Withdrawn
22
Completion rate
84%
Active now
52
Phase 2
15
Phase 3
117
Realized enrollment
754,534
First study year
2000
Years active
26
Match confidence
high
Enrollment velocity (inf)
29,021
Therapeutic
Areas
Cardiometabolic (cardiology/endocrinology/hepatology/renal, per ClinicalTrials.gov)
Breadth (conditions)
161
States
Texas
Recruitment (web observed)
Capability notes
4 active recruiting cardiometabolic trials (ClinicalTrials.gov)
Relationships
Sponsors
Abbott Medical Devices; Pfizer; Boehringer Ingelheim; Novo Nordisk A/S; Eli Lilly and Company; Bayer
CROs
MicroPort CRM; PPD Development, LP; Shanghai MicroPort Medical (Group) Co., Ltd.; Worldwide Clinical Trials
Owner / parent
Unknown
Capacity & people
Investigators
—
Coordinators
—
Emails
bold-HTN@estar.bio
Tech & DCT
Builds tech
Unknown
Tech stack
Unknown
Recruiting visible
Y
Notes
Surfaced via ClinicalTrials.gov mining (not on curated lists). 4 active recruiting cardiometabolic trials across 1 location(s). Actively-recruiting independent site = warm Intera lead; website/leadership not yet verified.
Recommendation features (sample indication)
Ind fit 1.00Liftability 1.00Overall68
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.